MELBOURNE, Australia, Nov. 22, 2016 /PRNewswire/ -- Mayne Pharma Group Limited (Mayne Pharma, ASX:MYX) has today announced the U.S. launch of IDT's generic temozolomide 5mg, 20mg, 100mg, 140mg, 180mg and 250mg capsules, which is a generic version of branded Temodar ®. Temozolomide capsules are indicated for the treatment of adult patients with newly diagnosed cancerous brain tumors known as glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. "The U.S. launch of IDT Australia Limited's first -ever drug product is a significant moment in the Company's history," said IDT's managing director , Dr .Paul MacLeman. "It represents profit growth via the development and commercialisation of IDT's own drug portfolio. Following on the back of last week's audit of IDT's manufacturing facility by the U.S. Food and Drug Administration, Temozolomide is the first of these products, with more to come." Temozolomide capsules had U.S. sales of approximately US$150m for the 12 months ending 30 September 2016, according to IMS Health. Mayne Pharma will distribute the drug on behalf of its partner, IDT Australia Ltd (IDT), which developed the product and is manufacturing the product. "Since entering the United States in 2012, Mayne Pharma has aggressively expanded its product portfolio, through internal product development, strategic acquisition, in-licensing and working collaboratively with partners like IDT ," said Scott Richards, CEO of Mayne Pharma. "Mayne Pharma now directly markets more than 50 products and we have a growing pipeline of more than 40 generic and branded drug products targeting U.S. markets with IMS Health sales greater than US$6 billion." For further information , please contact: IDT Australia LimitedDr Paul MacLemanManaging DirectorP: (03) 9801 8888 Monsoon Communications John BeveridgeP: (03) 9620 3333 About IDT IDT Australia Ltd recently acquired a portfolio of 23 generic drugs to manufacture and sell via US distribution partners. With IDT's 2013 Temozolomide ANDA filing this signifies IDT's move to rapidly become a specialty generics business with near term revenue build up.